Last reviewed · How we verify
NCT03941405: AlbuCAT
Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)
Phase 2 trial testing Albumin treatment in Hyponatremia With Excess Extracellular Fluid Volume in 52 participants. Completed in 30 January 2025.
28 December 2024
Quick facts
| Lead sponsor | Fundacion Clinic per a la Recerca Biomédica |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 52 |
| Start date | 1 February 2020 |
| Primary completion | 28 December 2024 |
| Estimated completion | 30 January 2025 |
| Sites | 3 locations across Spain |
Drugs / interventions tested
- Albumin treatment — full drug profile →
Conditions studied
- Hyponatremia With Excess Extracellular Fluid Volume — all drugs for Hyponatremia With Excess Extracellular Fluid Volume →
- Cirrhosis, Liver — all drugs for Cirrhosis, Liver →
Sponsor
Fundacion Clinic per a la Recerca Biomédica
Who can join
18 and older, any sex, with Hyponatremia With Excess Extracellular Fluid Volume or Cirrhosis, Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Controversies regarding albumin therapy in cirrhosis.
Trebicka J, Garcia-Tsao G. · · 2025 · cited 18× · PMID 37540192 · DOI 10.1097/hep.0000000000000521
Verify or expand the search:
- PubMed search for NCT03941405
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fundacion Clinic per a la Recerca Biomédica trials
Trials by the same sponsor.
- NCT07454096 — Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study · Phase 4 · not yet recruiting
- NCT07412873 — Study on Sexual Health and Self-perceived Quality of Life (PROMs) in Patients Treated for Cervical Cancer · Phase 4 · not yet recruiting
- NCT07163403 — First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptid · Phase 1 · recruiting
- NCT07105384 — Quantification Tools for a Novel Tau PET Marker in a Rare Neurological Disease: 18F-PI-2620 in Progressive Supranuclear · Phase 2 · active not recruiting
- NCT06896617 — Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET) · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03941405 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion Clinic per a la Recerca Biomédica
- Last refreshed: 28 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941405.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing